PMV Pharmaceuticals, Inc. — Form 8-K
Filed August 31, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
PMV Pharmaceuticals announced interim Phase 2 PYNNACLE trial data for rezatapopt in platinum-resistant/refractory ovarian cancer: 46% overall response rate (35/76 patients), median duration of response 10.0 months, favorable safety profile with 5% discontinuation due to adverse events. FDA feedback supports NDA submission strategy for accelerated approval; company plans to submit NDA in Q1 2027.
Why this rating
Lead asset showing clinically meaningful efficacy in cancer indication with regulatory path clarity and accelerated approval pathway. For $53.4M market-cap biotech, positive Phase 2 data supporting near-term NDA filing is transformational if approved.
Price action (we called it positive)
before filing · preread $1.04 ▼ 14.05% | at our read · unknown $1.21 | +10 min · unknown $1.21 ▲ 0.00% | +30 min · unknown $1.21 ▲ 0.00% | +1 hr pending | +4 hrs pending |
The stock had already moved +16.35% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from August 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.